Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.


Journal Article

Virologic and immunologic responses were examined for 33 human immunodeficiency virus (HIV)-infected children who participated for > or = 96 weeks in a phase 1/2 protocol of 16 weeks of indinavir monotherapy, followed by the addition of zidovudine and lamivudine. At week 96, a median increase of 199 CD4+ T cells/microL and a median decrease of 0.74 log(10) HIV RNA copies/mL were observed. The relationship between control of viral replication and CD4) T cell count was examined. Patients were categorized into 3 response groups on the basis of duration and extent of control of viral replication. Of 21 children with a transient decrease in virus load of > or = 0.7 log(10) HIV RNA copies/mL from baseline, 7 experienced sustained increases in CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cell counts. CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression.

Full Text

Duke Authors

Cited Authors

  • Jankelevich, S; Mueller, BU; Mackall, CL; Smith, S; Zwerski, S; Wood, LV; Zeichner, SL; Serchuck, L; Steinberg, SM; Nelson, RP; Sleasman, JW; Nguyen, BY; Pizzo, PA; Yarchoan, R

Published Date

  • April 1, 2001

Published In

Volume / Issue

  • 183 / 7

Start / End Page

  • 1116 - 1120

PubMed ID

  • 11237839

Pubmed Central ID

  • 11237839

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1086/319274


  • eng

Conference Location

  • United States